Navicixizumab

DB12634InvestigationalProtein Based Therapies

Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form and Delta-like protein 4
Curator reviewed
Code names: OMP-305B83

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Navicixizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.